Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer

Overview of attention for article published in Head & Neck, July 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Altmetric has seen 28 X posts from 27 X users, with an upper bound of 132,558 followers.

RT @MSK_RadOnc: New in #HeadandNeckJournal from the @MSKCancerCenter #radonc team: Chemoradiation with carboplatin and paclitaxel is an e…

RT @MSK_RadOnc: New in #HeadandNeckJournal from the @MSKCancerCenter #radonc team: Chemoradiation with carboplatin and paclitaxel is an e…

RT @MSK_RadOnc: New in #HeadandNeckJournal from the @MSKCancerCenter #radonc team: Chemoradiation with carboplatin and paclitaxel is an e…

RT @MSK_RadOnc: New in #HeadandNeckJournal from the @MSKCancerCenter #radonc team: Chemoradiation with carboplatin and paclitaxel is an e…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 24 additional X posts.